MedElevator
Войти в исследования Rheumatology advances in practice · 2026
A test of a conceptual model of uncertainty, benefit and burden in children and young people with juvenile dermatomyositis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Livermore Polly, Kupiec Klaudia H, Mulligan Kathleen, Hirani Shashi P, Gibson Faith, Deakin Claire, Ridout Deborah, Knight Andrea M, Wedderburn Lucy R, Feldman Brian M, Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDCBS), Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDCBS)
Аннотация
OBJECTIVES: Mental health concerns are highly prevalent in children and young people (CYP) with chronic conditions. This is further exacerbated by perceived feelings of illness uncertainty and illness burden, which have negative implications for CYP with childhood-onset chronic conditions and their families. Understanding the mechanisms that reduce health-related quality of life (HRQoL) and identifying resilience factors is important to improve outcomes for these vulnerable populations. The current study aimed to assess HRQoL in CYP with juvenile dermatomyositis (JDM) and to test a new conceptual model of illness representations and resilience in depression and anxiety.
METHODS: CYP ages ≥8 years who were enrolled in the UK-wide JDM cohort and Biomarker Study (JDCBS) in 15 UK National Health Service tertiary paediatric rheumatology services were invited to complete five validated paediatric measures: PedsQL 4.0 Core, PedsQL 3.0 Rheumatology Module, Paediatric Index of Emotional Distress (PI-ED), Childhood Uncertainty in Illness Scale (CUIS) and Benefit and Burden Scale for Children (BBSC). Data were analysed using descriptive statistics and structural equation modelling.
RESULTS: Results showed that the HRQoL in CYP with JDM is affected as a result of their chronic condition. Moreover, the proposed model revealed that illness uncertainty and burden are key driving factors that cause an increase in anxiety and depression, while benefit finding did not ameliorate poor mental health outcomes.
CONCLUSION: Addressing illness uncertainty and reducing the perceived disease burden is vital to improve HRQoL and well-being in CYP with JDM who struggle to cope with the unpredictable nature of their disease.
METHODS: CYP ages ≥8 years who were enrolled in the UK-wide JDM cohort and Biomarker Study (JDCBS) in 15 UK National Health Service tertiary paediatric rheumatology services were invited to complete five validated paediatric measures: PedsQL 4.0 Core, PedsQL 3.0 Rheumatology Module, Paediatric Index of Emotional Distress (PI-ED), Childhood Uncertainty in Illness Scale (CUIS) and Benefit and Burden Scale for Children (BBSC). Data were analysed using descriptive statistics and structural equation modelling.
RESULTS: Results showed that the HRQoL in CYP with JDM is affected as a result of their chronic condition. Moreover, the proposed model revealed that illness uncertainty and burden are key driving factors that cause an increase in anxiety and depression, while benefit finding did not ameliorate poor mental health outcomes.
CONCLUSION: Addressing illness uncertainty and reducing the perceived disease burden is vital to improve HRQoL and well-being in CYP with JDM who struggle to cope with the unpredictable nature of their disease.